Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Total Non-Current Liabilities (2016 - 2025)

Anaptysbio filings provide 10 years of Total Non-Current Liabilities readings, the most recent being $50.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 14.92% year-over-year to $50.7 million, compared with a TTM value of $50.7 million through Dec 2025, down 14.92%, and an annual FY2025 reading of $50.7 million, down 14.92% over the prior year.
  • Total Non-Current Liabilities hit $50.7 million in Q4 2025 for Anaptysbio, roughly flat from $50.7 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $305.9 million in Q3 2022, with the low at $35.5 million in Q4 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $53.2 million (2023), compared with a mean of $65.4 million.
  • The sharpest move saw Total Non-Current Liabilities surged 79.35% in 2021, then crashed 81.8% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $35.5 million in 2021, then grew by 23.4% to $43.9 million in 2022, then increased by 21.91% to $53.5 million in 2023, then rose by 11.33% to $59.5 million in 2024, then fell by 14.92% to $50.7 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $50.7 million, $50.7 million, and $48.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.